1. 323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer. (13th November 2020) Authors: Randall, L; Marth, C; Vulsteke, C; Jesús Rubio, M; Makker, V; Braicu, I; McNeish, I; Madry, R; Ayhan, A; Hasegawa, K; Wu, X; Dutta, L; Xu, C; Keefe, S; Lee, J; Pignata, S Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study. (1st November 2019) Authors: González-Martín, A; Pothuri, B; Vergote, I; Christensen, RD; Graybill, W; Mirza, MR; McCormick, C; Lorusso, D; Hoskins, P; Freyer, G; Baumann, K; Jardon, K; Redondo, A; Moore, RG; Vulsteke, C; O'Cearbhaill, RE; Lund, B; Backes, F; Barretina-Ginesta, P; Haggerty, AF Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗